MBX Biosciences Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022
Net Income	-86.61	-86.97	-61.92	-32.56	-26.14
Depreciation & Amortization	0.24	0.25	0.24	0.16	0.06
Stock-Based Compensation	12.32	8.68	5.22	2.04	0.31
Other Adjustments	-2.71	-3.48	-2.82	-0.88	1.36
Changes in Accounts Payable	3.08	-2.46	3.93	0.41	0.67
Changes in Accrued Expenses	1.38	6.8	3.17	0.05	1.45
Changes in Other Operating Activities	-4.86	-2.77	-2.5	-1.19	-0.83
Operating Cash Flow	-77.48	-79.95	-54.68	-31.98	-23.12
Capital Expenditures	-2.34	-1.93	-0.87	-0.13	-0.44
Purchases of Investments	-453.41	-358.15	-239.47	-63.8	-20.22
Proceeds from Sale of Investments	271.72	276.37	79.75	33	9.25
Investing Cash Flow	-54.06	-83.71	-160.6	-30.93	-11.41
Long-Term Debt Issued	-	-	-	-	10
Net Long-Term Debt Issued (Repaid)	-	-	-	-	10
Issuance of Common Stock	90.22	190.36	174.95	0.74	0.03
Net Common Stock Issued (Repurchased)	90.22	190.36	174.95	0.74	0.03
Issuance of Preferred Stock	-	-	63.5	68.51	36.49
Net Preferred Stock Issued (Repurchased)	-	-	63.5	68.51	36.49
Other Financing Activities	-	-0.77	-4.34	-0.03	-0.46
Financing Cash Flow	0.67	189.59	234.1	69.22	46.06
Net Cash Flow	15.52	25.94	18.83	6.31	11.53
Free Cash Flow	-79.82	-81.88	-55.56	-32.11	-23.56
Free Cash Flow Per Share	-2.01	-2.24	-5.22	-31.52	-35.33
Levered Free Cash Flow	-89.11	-87.08	-57.96	-33.27	-15.23
Unlevered Free Cash Flow	-101.29	-98.16	-64.23	-36.02	-24.26

SEC Filings: 10-K · 10-Q